Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis

Abstract

Background:The programmed cell death ligand-1 (PD-L1)/programmed cell death-1 (PD-1) pathway is important in metastatic renal cell carcinoma (mRCC). However, some dissimilarities between anti-PD-1 and anti-PD-L1 inhibitors have emerged. We aimed to assess differences between anti-PD-1 and anti-PD-L1 combination immunotherapies as first-line treatments in mRCC patients. Methods: Multiple databases (PubMed, Web of Science, and Scopus) were searched for articles published until March 2021. Studies were eligible if they compared overall survival (OS), progression-free survival (PFS), objective response rates (ORR), complete response rates (CRR), and adverse events. Results: Five studies met the eligibility criteria. PD-1 combination therapy was associated with significantly better OS and PFS and higher ORR and CRR than sunitinib (hazard ratio [HR]: 0.

Reassessment of the Efficacy of Carboplatin for Metastatic Urothelial Carcinoma in the Era of Immunotherapy: A Systematic Review and Meta-analysis

“…Indeed, a much larger proportion (48%) of patients undergoing chemotherapy received subsequent ICI therapy in the KEYNOTE361 trial than in the other trials, likely contributing to the favorable OS outcomes in its chemotherapy arm as well as to the underestimation of the efficacy of pembrolizumab in patients receiving ICI therapy [12]. Moreover, it must be noted that, despite being uniformly categorized as immunotherapy, ICIs included both PD-1 and PD-L1 inhibitors, which differ in their mechanisms of action and possibly efficacy [49]. Second, while the NMA involved an indirect approach to compare outcomes from the RCTs, this approach falls short of a head-to-head comparison.…”

A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib

“…The role of PD‐L1 expression as a predictive biomarker should be elucidated in future trials. According to the other recent meta‐analysis, 22 anti‐PD‐1 agents showed superior oncological outcomes to anti‐PD‐L1 agents. Conversely, anti‐PD‐L1 agents were superior to anti‐PD‐1 agents in their safety profiles.…”

What's The Next Era Of Immune Checkpoint Inhibitors Of Renal Cell Carcinoma In Clinical Practice: An Evidence From Extended Bibliometric Analysis

“…According to the analysis of the results of Table 3, anti-PD-1 displayed a great effect on the treatment of RCC, and anti-CTLA-4 may be close to a curtain call of clinical research. Keiichiro et al revealed that patients with metastatic RCC who received anti-PD-1 combination therapy in rst-line may obtain more bene ts than anti-PD-L1 combination therapy [35]. This still requires researchers to further explore.…”